v3.25.1
Note 13 - Share Incentive Plans
3 Months Ended
Mar. 31, 2025
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

Note 13. Share Incentive Plans

 

On  March 22, 2021, the Company’s Board of Directors adopted the Turning Point Brands, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which awards  may be granted to employees, non-employee directors, and consultants. In addition, the 2021 Plan provides for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2021 Plan, 1,290,000 shares, plus 100,052 shares remaining available for issuance under the 2015 Equity Incentive Plan (the “2015 Plan”), of TPB Common Stock are reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past or future services or the attainment of certain performance goals. The 2021 Plan is scheduled to terminate on  March 21, 2031. The 2021 Plan is administered by the compensation committee (the “Committee”) of the Company’s Board of Directors. The Committee determines the vesting criteria for the awards, with such criteria to be specified in the award agreement. As of March 31, 2025, net of forfeitures, there were 433,481 Restricted Stock Units (“RSUs”), 122,570 options and 107,978 Performance Based Restricted Stock Units (“PRSUs”) granted under the 2021 Plan. There are 726,023 shares available for future grant under the 2021 Plan.

 

On  April 28, 2016, the Board of Directors of the Company adopted the 2015 Plan, pursuant to which awards could have been granted to employees, non-employee directors, and consultants. In addition, the 2015 Plan provided for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Upon adoption of the 2021 Plan, the 2015 Plan was terminated, and the Company determined no additional grants would be made under the 2015 Plan. However, all awards issued under the 2015 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected. There are no shares available for grant under the 2015 Plan.

 

Stock option activity for the 2015 and 2021 Plans is summarized below:

 

      

Weighted

  

Weighted

 
  

Stock

  

Average

  

Average

 
  

Option

  

Exercise

  

Grant Date

 
  

Shares

  

Price

  

Fair Value

 

Outstanding, December 31, 2023

  656,951  $29.79  $9.18 
             

Granted

  54,289   27.19   9.21 

Exercised

  (132,572)  21.36   6.97 

Forfeited

  (42,878)  38.11   11.94 

Outstanding, December 31, 2024

  535,790  $30.69  $9.51 
             

Exercised

  (25,104)  38.77   12.27 

Forfeited

  (2,643)  36.11   10.88 

Outstanding, March 31, 2025

  508,043  $30.26  $9.36 

 

Under the 2015 and 2021 Plans, the total intrinsic value of options exercised during the three months ended March 31, 2025 and 2024, was $0.6 million, and $0.0 million, respectively.

 

At March 31, 2025, under the 2015 and 2021 Plans, the risk-free interest rate is based on the U.S. Treasury rate for the expected life at the time of grant. The expected volatility is based on the average long-term historical volatilities of peer companies. We intend to continue to consistently use the same group of publicly traded peer companies to determine expected volatility until sufficient information regarding volatility of our share price becomes available or until the selected companies are no longer suitable for this purpose. Due to our limited trading history, we are using the simplified method presented by SEC Staff Accounting Bulletin No. 107 to calculate expected holding periods, which represent the periods of time for which options granted are expected to be outstanding. We will continue to use this method until we have sufficient historical exercise experience to give us confidence in the reliability of our calculations. The fair values of these options were determined using the Black-Scholes option pricing model.

 

The following table outlines the assumptions based on the number of options granted under the 2015 Plan.

 

  

February 10,

  

May 17,

  

March 7,

  

March 20,

  

March 18,

  

February 18,

 
  

2017

  

2017

  

2018

  

2019

  

2020

  

2021

 

Number of options granted

  40,000   93,819   98,100   155,780   155,000   100,000 

Options outstanding at March 31, 2025

  20,000   30,969   47,767   87,607   58,214   64,900 

Number exercisable at March 31, 2025

  20,000   30,969   47,767   87,607   58,214   64,900 

Exercise price

 $13.00  $15.41  $21.21  $47.58  $14.85  $51.75 

Remaining lives

  1.87   2.13   2.94   3.97   4.97   5.89 

Risk free interest rate

  1.89%  1.76%  2.65%  2.34%  0.79%  0.56%

Expected volatility

  27.44%  26.92%  28.76%  30.95%  35.72%  28.69%

Expected life

  6.000   6.000   6.000   6.000   6.000   6.000 

Dividend yield

  -   -   0.83%  0.42%  1.49%  0.55%

Fair value at grant date

 $3.98  $4.60  $6.37  $15.63  $4.41  $13.77 

 

The following table outlines the assumptions based on the number of options granted under the 2021 Plan.

 

  

May 17,

  

March 14,

  

April 29,

  

May 12,

  

March 11,

 
  

2021

  

2022

  

2022

  

2023

  

2024

 

Number of options granted

  7,500   100,000   14,827   77,519   54,289 

Options outstanding at March 31, 2025

  7,500   53,005   6,273   77,519   54,289 

Number exercisable at March 31, 2025

  7,500   53,005   6,273   77,519   54,289 

Exercise price

 $45.05  $30.46  $31.39  $20.71  $27.19 

Remaining lives

  6.13   6.96   7.08   8.12   8.95 

Risk free interest rate

  0.84%  2.10%  2.92%  3.41%  4.06%

Expected volatility

  31.50%  35.33%  35.33%  34.51%  35.09%

Expected life

  6.000   6.000   6.000   5.186   5.186 

Dividend yield

  0.63%  1.01%  0.98%  1.61%  1.26%

Fair value at grant date

 $13.23  $10.23  $11.07  $6.45  $9.21 

 

The Company has recorded compensation expense related to the options based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the options on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the options of approximately $0.0 million and $0.3 million for the three months ended March 31, 2025 and 2024, respectively. At March 31, 2025, there is no remaining compensation expense related to options. 

 

PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the measurement date, which is no more than 65 days after the performance period provided the applicable service and performance conditions are satisfied. As of March 31, 2025, there are 286,655 PRSUs outstanding. The following table outlines the PRSUs granted and outstanding as of March 31, 2025.

 

  

February 18,

  

March 14,

  

May 4,

  

March 1,

  

April 1,

  

March 3,

 
  

2021

  

2022

  

2023

  

2024

  

2024

  

2025

 

Number of PRSUs granted

  100,000   49,996   133,578   111,321   8,242   41,137 

PRSUs outstanding at March 31, 2025

  69,190   21,745   69,972   78,017   6,594   41,137 

Fair value as of grant date

 $51.75  $30.46  $22.25  $26.52  $29.12  $70.34 

Remaining lives

  0.75   1.75   0.75   1.75   1.75   2.75 

 

The Company recorded compensation expense related to the PRSUs of approximately $0.7 million and $0.9 million in the consolidated statements of income for the three months ended March 31, 2025 and 2024, respectively, based on the probability of achieving the performance condition. Total unrecognized compensation expense related to these awards at March 31, 2025, is $4.3 million which will be expensed over the service periods based on the probability of achieving the performance condition.

 

The Company has granted 186,669 RSUs which are outstanding and vest over one to five years. The following table outlines the RSUs granted and outstanding as of March 31, 2025.

 

  

March 14,

  

April 29,

  

May 5,

  

March 1,

  

April 1,

  

May 8,

  

March 3,

  

March 5,

 
  

2022

  

2022

  

2023

  

2024

  

2024

  

2024

  

2025

  

2025

 

Number of RSUs granted

  50,004   4,522   130,873   105,257   5,495   16,905   36,843   14,921 

RSUs outstanding at March 31, 2025

  21,113   1,263   34,564   57,433   3,627   16,905   36,843   14,921 

Fair value as of grant date

 $30.46  $31.39  $22.25  $26.52  $29.12  $33.13  $70.34  $67.02 

Remaining lives

  1.75   1.75   1.00   2.00   2.00   0.25   3.00   1.00 

 

The Company has recorded compensation expense related to the RSUs based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the RSUs on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the RSUs of approximately $1.0 million and $0.9 million for the three months ended March 31, 2025 and 2024. Total unrecognized compensation expense related to RSUs at March 31, 2025, is $4.7 million, which will be expensed over 2.22 years.